Precision Sleep Treatment: How CBT-I, Medicines

Why Are Clinicians Treating Sleep as a Medical Therapy?

A Nature Medicine article examining sleep as therapy reflects a broader shift in clinical care: sleep is increasingly assessed as a treatment target with measurable symptoms, underlying mechanisms and potential harms. Persistent insomnia can impair concentration, mood and daytime performance, but inadequate sleep may also arise from obstructive sleep apnea, restless legs syndrome, circadian disorders, pain, medication effects or another medical condition.

This distinction matters because prescribing a sedative without identifying the cause can delay appropriate care. A clinical assessment may include the timing and duration of symptoms, daytime impairment, work schedules, substance use and a review of medicines. Sleep diaries or wearable data can support pattern recognition, although consumer devices cannot independently diagnose most sleep disorders.

What Is the First-Line Treatment for Chronic Insomnia?

Cognitive behavioral therapy for insomnia, commonly called CBT-I, combines several techniques rather than relying on general sleep-hygiene advice alone. Treatment may include stimulus control, carefully planned time in bed, cognitive strategies and relaxation methods. The American College of Physicians recommends CBT-I as initial treatment for adults with chronic insomnia, and it can be delivered individually, in groups or through validated digital programs.

CBT-I aims to change the behaviors and expectations that maintain insomnia, so benefits may persist after treatment ends. Clinicians should adapt the program for people with conditions such as bipolar disorder, epilepsy, untreated sleep apnea or occupations in which temporary daytime sleepiness could create safety risks. Access remains a practical challenge because trained clinicians and evidence-based programs are not universally available.

When Can Sleep Medicines Be Part of Treatment?

Available medicines act through different pathways. Dual orexin receptor antagonists reduce wake-promoting signaling, while other options influence GABA, melatonin or histamine systems. Drug selection should match the main complaint, such as difficulty falling asleep or repeated nighttime awakening, while considering age, pregnancy, breathing disorders, liver function, fall risk and interactions with alcohol, opioids or other sedating medicines.

No sleep medicine is risk-free. Potential problems include next-day impairment, falls, unusual sleep behaviors, tolerance or dependence, depending on the drug. Treatment should therefore use a defined goal, the lowest effective dose and scheduled reassessment. Patients should not combine prescription sleep medicines with alcohol or stop certain sedatives abruptly without clinical guidance.